Coronary Sinus Stent Effective in Refractory Angina

November 07, 2013

RICHMOND, BC – Neovasc, the makers of a percutaneous treatment for refractory angina, announced today that the coronary sinus Reducer stent effectively reduced angina scores when compared with a sham procedure in patients with refractory angina[1].

The company announced the top-line results in a press release, reporting that the 104-patient CORSIRA study achieved the primary end point, which is a decrease in two or more Canadian Cardiovascular Society (CCS) angina score grades from baseline to six months in Reducer-treated patients compared with patients who were treated with a control procedure.

The company said the full data set is being submitted to the American College of Cardiology for consideration as a late-breaking clinical trial as well as for publication in a peer-reviewed journal. In addition, the researchers are currently analyzing secondary end points, including technical and procedural success rates, periprocedural adverse events, major adverse events, and exercise tolerance testing.

With treatment, the coronary sinus Reducer stent is implanted percutaneously into the coronary sinus and works by modulating the outflow of blood from the heart and to help redistribute flow to ischemic areas of the heart. The Reducer has CE Mark approval in the European Union for the treatment of refractory angina.

Neovasc sponsored the COSIRA study.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.